PHENYLBUTYRATE

( DrugBank: - / KEGG DRUG: - )

---

12 diseases

2. 筋萎縮性側索硬化症

---

臨床試験数 : 786 / 薬物数 : 550 - (DrugBank : 182) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 232 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

3. 脊髄性筋萎縮症

---

臨床試験数 : 297 / 薬物数 : 143 - (DrugBank : 32) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 82 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

6. パーキンソン病

---

臨床試験数 : 2,586 / 薬物数 : 1,871 - (DrugBank : 354) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 205 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

8. ハンチントン病

---

臨床試験数 : 276 / 薬物数 : 185 - (DrugBank : 58) / 標的遺伝子数 : 86 - 標的パスウェイ数 : 160 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

15. 封入体筋炎

---

臨床試験数 : 46 / 薬物数 : 41 - (DrugBank : 14) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 130 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

93. 原発性胆汁性胆管炎

---

臨床試験数 : 352 / 薬物数 : 206 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 119 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

94. 原発性硬化性胆管炎

---

臨床試験数 : 177 / 薬物数 : 120 - (DrugBank : 48) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 148 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

244. メープルシロップ尿症

---

臨床試験数 : 3 / 薬物数 : 4 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

251. 尿素サイクル異常症

---

臨床試験数 : 68 / 薬物数 : 50 - (DrugBank : 19) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 4 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

297. アラジール症候群

---

臨床試験数 : 45 / 薬物数 : 15 - (DrugBank : 8) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 5 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

299. 嚢胞性線維症

---

臨床試験数 : 1,826 / 薬物数 : 1,271 - (DrugBank : 246) / 標的遺伝子数 : 118 - 標的パスウェイ数 : 180 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

338. 進行性家族性肝内胆汁うっ滞症

---

臨床試験数 : 62 / 薬物数 : 14 - (DrugBank : 5) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 3 

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries